Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204654 | 0.90 | HRH4 (0.33) | HRH4SLC6A3ACLYSLC6A4 | |
| SCHEMBL3194668 | 0.89 | RORC (0.35) | HRH4SLC6A3ACLY | |
| SCHEMBL3213223 | 0.89 | HRH4 (0.31) | HRH4ACLY | |
| SCHEMBL3202779 | 0.88 | LMNA (0.38) | HRH4ACLYHTTSMN1; SMN2RXFP1 | |
| SCHEMBL3122563 | 0.88 | PCSK9 (0.33) | HRH4ACLY | |
| SCHEMBL3208426 | 0.88 | ACLY (0.34) | HRH4ACLY | |
| SCHEMBL3212622 | 0.87 | PDE4A (0.33) | HRH4SLC6A3ACLYSLC6A4 | |
| SCHEMBL7947884 | 0.87 | HRH4 (0.33) | HRH4ACLY | |
| SCHEMBL3211858 | 0.84 | HRH4 (0.40) | HRH4KMT2A | |
| SCHEMBL3207210 | 0.83 | TAAR1 (0.43) | HRH4ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | HRH4 442/4885SLC6A3 534/4885ACLY 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.